Cannabis-derived treatment reduces agitation in late-stage dementia patients, clinical trial shows

A groundbreaking clinical trial demonstrates that a medical formulation containing THC and CBD—two active compounds from cannabis—significantly reduces agitation in hospice-eligible dementia patients compared to placebo. This first-of-its-kind study offers new hope for managing behavioral symptoms in late-stage dementia, a challenging aspect of end-of-life care. Agitation in dementia patients often leads to distress for both patients and caregivers, and current treatment options are limited. The findings suggest cannabis-derived medications could provide a safer, more effective alternative for symptom management in this vulnerable population. Researchers emphasize the need for further studies to establish optimal dosing and long-term safety profiles.